Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV

Inclusion Criteria: * Aged 56 to 70 days inclusive on the day of inclusion * Born at full term pregnancy (\>37 weeks) with a birth weight ≥ 2.5 kg * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial procedures Exclusion Criteria: * Participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination * Planned participation in another clinical trial during the present trial period. * Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy. * Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances. * Chronic illness at a stage that could interfere with trial conduct or completion. * Blood or blood-derived products received in the past or planned administration during the trial (including immunoglobulins). * Any vaccination in the 3 weeks preceding the first trial vaccination. * History of diphtheria, tetanus, pertussis, poliomyelitis infection (confirmed either clinically, serologically or microbiologically). * Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases with the trial vaccine or another vaccine. * Thrombocytopenia or a bleeding disorders contraindicating intramuscular vaccination * History of major neurological diseases or seizures. * Febrile illness (rectal temperature ≥ 38.0°C or axillary temperature ≥ 37.4°C) on the day of inclusion. * Known family history of congenital or genetic immuno-deficiency.